Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710434 | 1.00 | SMYD3 (1.00) | SMYD3NPC1RAB9AKMT2APKM | |
| SCHEMBL21489853 | 0.86 | SMYD3 (1.00) | SMYD3NPC1RAB9A | |
| SCHEMBL19701231 | 0.86 | SMYD3 (1.00) | SMYD3NPC1RAB9A | |
| SCHEMBL19709999 | 0.86 | SMYD3 (1.00) | SMYD3NPC1RAB9AKMT2AADRB2 | |
| SCHEMBL21490104 | 0.86 | SMYD3 (1.00) | SMYD3NPC1RAB9AKMT2AADRB2 | |
| SCHEMBL14198233 | 0.81 | SMYD3 (0.74) | SMYD3NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL12852600 | 0.79 | SMYD3 (0.64) | SMYD3NPC1RAB9AKMT2APKM | |
| SCHEMBL23951315 | 0.78 | SMYD3 (0.85) | SMYD3NPC1RAB9AKMT2APKM | |
| SCHEMBL21489836 | 0.77 | SMYD3 (1.00) | SMYD3NPC1RAB9A | |
| SCHEMBL6455623 | 0.77 | SMYD3 (0.69) | SMYD3NPC1RAB9APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885NPC1 3734/4885RAB9A 890/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885NPC1 3830/4885RAB9A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.